Xponance Inc. Buys 241 Shares of Glaukos Co. (NYSE:GKOS)

Xponance Inc. grew its stake in shares of Glaukos Co. (NYSE:GKOS) by 8.4% in the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 3,118 shares of the medical instruments supplier’s stock after acquiring an additional 241 shares during the period. Xponance Inc.’s holdings in Glaukos were worth $369,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of GKOS. Evergreen Capital Management LLC raised its stake in Glaukos by 26.8% in the second quarter. Evergreen Capital Management LLC now owns 2,945 shares of the medical instruments supplier’s stock worth $349,000 after buying an additional 623 shares in the last quarter. Public Sector Pension Investment Board raised its stake in Glaukos by 10.9% in the second quarter. Public Sector Pension Investment Board now owns 110,905 shares of the medical instruments supplier’s stock worth $13,126,000 after buying an additional 10,873 shares in the last quarter. Mount Yale Investment Advisors LLC bought a new position in Glaukos in the second quarter worth approximately $212,000. Sei Investments Co. raised its stake in Glaukos by 51.6% in the second quarter. Sei Investments Co. now owns 108,546 shares of the medical instruments supplier’s stock worth $12,847,000 after buying an additional 36,933 shares in the last quarter. Finally, Brighton Jones LLC bought a new position in Glaukos in the second quarter worth approximately $208,000. Institutional investors own 99.04% of the company’s stock.

Analyst Upgrades and Downgrades

GKOS has been the subject of a number of recent research reports. Piper Sandler boosted their price objective on shares of Glaukos from $110.00 to $140.00 and gave the stock an “overweight” rating in a research note on Thursday, August 1st. Wells Fargo & Company upped their price target on Glaukos from $120.00 to $135.00 and gave the stock an “overweight” rating in a research report on Thursday, August 1st. Needham & Company LLC upped their price target on Glaukos from $131.00 to $137.00 and gave the stock a “buy” rating in a research report on Thursday, August 1st. Stifel Nicolaus upped their price target on Glaukos from $130.00 to $145.00 and gave the stock a “buy” rating in a research report on Tuesday, September 3rd. Finally, StockNews.com downgraded Glaukos from a “hold” rating to a “sell” rating in a research report on Friday, August 30th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and eight have given a buy rating to the company. According to data from MarketBeat.com, Glaukos currently has a consensus rating of “Moderate Buy” and a consensus price target of $129.82.

Glaukos Price Performance

NYSE GKOS opened at $126.55 on Wednesday. Glaukos Co. has a 1 year low of $59.22 and a 1 year high of $136.60. The company has a debt-to-equity ratio of 0.19, a current ratio of 5.48 and a quick ratio of 4.67. The company has a market cap of $6.37 billion, a price-to-earnings ratio of -43.94 and a beta of 1.03. The stock’s fifty day moving average price is $125.54 and its 200 day moving average price is $113.44.

Glaukos (NYSE:GKOS) last posted its quarterly earnings results on Wednesday, July 31st. The medical instruments supplier reported ($0.52) EPS for the quarter, meeting the consensus estimate of ($0.52). Glaukos had a negative net margin of 47.39% and a negative return on equity of 22.51%. The company had revenue of $95.70 million for the quarter, compared to analyst estimates of $88.86 million. During the same period in the prior year, the company earned ($0.55) earnings per share. The firm’s revenue was up 19.0% on a year-over-year basis. As a group, equities research analysts forecast that Glaukos Co. will post -2.18 earnings per share for the current year.

Insider Transactions at Glaukos

In other news, Director Gilbert H. Kliman sold 3,000 shares of the stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $130.67, for a total transaction of $392,010.00. Following the sale, the director now directly owns 32,336 shares of the company’s stock, valued at approximately $4,225,345.12. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. In other Glaukos news, Director Aimee S. Weisner sold 25,000 shares of the stock in a transaction dated Thursday, August 8th. The shares were sold at an average price of $120.00, for a total value of $3,000,000.00. Following the completion of the sale, the director now owns 30,119 shares in the company, valued at approximately $3,614,280. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Gilbert H. Kliman sold 3,000 shares of the stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $130.67, for a total transaction of $392,010.00. Following the completion of the sale, the director now owns 32,336 shares of the company’s stock, valued at approximately $4,225,345.12. The disclosure for this sale can be found here. Insiders have sold a total of 41,500 shares of company stock valued at $5,099,000 in the last ninety days. 6.40% of the stock is currently owned by corporate insiders.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.